{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:01Z","timestamp":1772496001039,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["academicradiology.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Academic Radiology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.acra.2025.11.046","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T04:54:37Z","timestamp":1765860877000},"page":"990-1004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Postoperative Adjuvant CTACE vs DEB-TACE Combined with Tislelizumab and Lenvatinib in BCLC Stage B\/C Hepatocellular Carcinoma: A Propensity Score-Matched Analysis of Survival Outcomes"],"prefix":"10.1016","volume":"33","author":[{"given":"Yuan","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honghan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4950-3613","authenticated-orcid":false,"given":"Zhengrong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.acra.2025.11.046_bib1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.hbpd.2023.10.009","article-title":"Comprehensive review of hepatocellular carcinoma with portal vein tumor thrombus: state of art and future perspectives","volume":"23","author":"Gavriilidis","year":"2024","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"5","key":"10.1016\/j.acra.2025.11.046_bib2","first-page":"235","article-title":"Safety, efficacy, and survival of different transarterial chemoembolization techniques in the management of unresectable hepatocellular carcinoma: a comparative single-center analysis","volume":"150","author":"Schindler","year":"2024","journal-title":"J\u00a0Cancer Res\u00a0Clin\u00a0Oncol"},{"issue":"4","key":"10.1016\/j.acra.2025.11.046_bib3","doi-asserted-by":"crossref","first-page":"616","DOI":"10.21037\/hbsn-23-363","article-title":"Adjuvant camrelizumab plus apatinib in resected hepatocellular carcinoma with microvascular invasion: a multi-center real world study","volume":"13","author":"Ouyang","year":"2024","journal-title":"Hepatobiliary Surg\u00a0Nutr"},{"issue":"5","key":"10.1016\/j.acra.2025.11.046_bib4","first-page":"541","article-title":"Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J\u00a0Natl Compr\u00a0Cancer Netw"},{"key":"10.1016\/j.acra.2025.11.046_bib5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ctrv.2018.11.002","article-title":"Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence","volume":"72","author":"Raoul","year":"2019","journal-title":"Cancer Treat\u00a0Rev"},{"issue":"5","key":"10.1016\/j.acra.2025.11.046_bib6","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.4251\/wjgo.v16.i5.2225","article-title":"Multidisciplinary comprehensive treatment of massive hepatocellular carcinoma with hemorrhage: a case report and review of literature","volume":"16","author":"Kou","year":"2024","journal-title":"World J\u00a0Gastrointestinal Oncol"},{"issue":"2","key":"10.1016\/j.acra.2025.11.046_bib7","first-page":"255","article-title":"Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma","volume":"111","author":"Golfieri","year":"2014","journal-title":"Br\u00a0J\u00a0Cancer"},{"issue":"3","key":"10.1016\/j.acra.2025.11.046_bib8","first-page":"1150","article-title":"Comparison of treatment response, survival and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres\u00ae microspheres versus conventional transarterial chemoembolization in treating hepatocellular carcinoma","volume":"24","author":"Zhao","year":"2019","journal-title":"J\u00a0BUON"},{"key":"10.1016\/j.acra.2025.11.046_bib9","article-title":"EASL clinical practice guidelines on the management of hepatocellular carcinoma","author":"European Association for the Study of the Liver","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.acra.2025.11.046_bib10","first-page":"1767","article-title":"Whether adjuvant TACE plus TKI therapy is more effective than TACE alone in HCC patients at high risks of recurrence following radical hepatectomy","volume":"12","author":"Li","year":"2025","journal-title":"J\u00a0Hepatocell\u00a0Carcinoma"},{"issue":"11","key":"10.1016\/j.acra.2025.11.046_bib11","first-page":"2188","article-title":"Adjuvant transarterial chemoembolization improves survival outcomes in hepatocellular carcinoma with microvascular invasion: a\u00a0systematic review and meta-analysis","volume":"45","author":"Chen","year":"2019","journal-title":"Eur\u00a0J\u00a0Surg\u00a0Oncol\u00a0J\u00a0Eur\u00a0Soc\u00a0Surg\u00a0Oncol\u00a0Br\u00a0Assoc\u00a0Surg\u00a0Oncol"},{"issue":"2","key":"10.1016\/j.acra.2025.11.046_bib12","first-page":"142","article-title":"Adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma with microvascular invasion: a systematic review and meta-analysis","volume":"44","author":"Shen","year":"2020","journal-title":"Clin\u00a0Res\u00a0Hepatol\u00a0Gastroenterol"},{"key":"10.1016\/j.acra.2025.11.046_bib13","article-title":"TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: A multicenter cohort study","volume":"15","author":"Chen","year":"2024","journal-title":"Front\u00a0Immunol"},{"key":"10.1016\/j.acra.2025.11.046_bib14","article-title":"Safety and efficacy of DEB-TACE in combination with lenvatinib and camrelizumab for the treatment of unresectable hepatocellular carcinoma (uHCC): a two-centre retrospective study","volume":"15","author":"Xuexian","year":"2024","journal-title":"Front\u00a0Immunol"},{"issue":"8","key":"10.1016\/j.acra.2025.11.046_bib15","first-page":"4660","article-title":"Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: a global-scale, cross-sectional, and large-sample informatics study","volume":"110","author":"Guo","year":"2024","journal-title":"Int\u00a0J\u00a0Surg"},{"issue":"10","key":"10.1016\/j.acra.2025.11.046_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040296","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"4","author":"von Elm","year":"2007","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.acra.2025.11.046_bib17","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"20","key":"10.1016\/j.acra.2025.11.046_bib18","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.acra.2025.11.046_bib19","article-title":"Efficacy of tislelizumab plus lenvatinib in hepatocellular carcinoma after curative hepatectomy: a real-world study","volume":"16","author":"Chen","year":"2025","journal-title":"Front\u00a0Immunol"},{"key":"10.1016\/j.acra.2025.11.046_bib20","first-page":"1119","article-title":"Lenvatinib monotherapy versus lenvatinib in combination with PD-1 blockades as re-challenging treatment for patients with metastatic osteosarcoma: a real-world study","volume":"19","author":"Song","year":"2025","journal-title":"Drug Des\u00a0Develop\u00a0Ther"},{"issue":"7","key":"10.1016\/j.acra.2025.11.046_bib21","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.acra.2025.11.046_bib22","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.28453","article-title":"Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data","volume":"64","author":"Lencioni","year":"2016","journal-title":"Hepatology"},{"issue":"10126","key":"10.1016\/j.acra.2025.11.046_bib23","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.acra.2025.11.046_bib24","first-page":"103","volume":"85","author":"Gavanier","year":"2016","journal-title":"Eur\u00a0J\u00a0Radiol"},{"issue":"1","key":"10.1016\/j.acra.2025.11.046_bib25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermo-Sifiliograficas"},{"issue":"5","key":"10.1016\/j.acra.2025.11.046_bib26","first-page":"583","article-title":"Comparison of treatment response and survival profiles between drug-eluting bead transarterial chemoembolization and conventional transarterial chemoembolization in chinese hepatocellular carcinoma patients: a prospective cohort study","volume":"27","author":"Wen","year":"2019","journal-title":"Oncol\u00a0Res"},{"issue":"1","key":"10.1016\/j.acra.2025.11.046_bib27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12672-024-01030-z","article-title":"Clinical research progress of callisperes\u00ae of drug-loaded microsphere arterial chemoembolisation in the treatment of solid tumors","volume":"15","author":"Wang","year":"2024","journal-title":"Discover Oncol"},{"key":"10.1016\/j.acra.2025.11.046_bib28","first-page":"127","article-title":"Drug-eluting embolic microspheres for local drug delivery - state of the art","volume":"262","author":"Fuchs","year":"2017","journal-title":"J\u00a0Control\u00a0Release\u00a0Offl J\u00a0Control\u00a0Release Soc"},{"issue":"12","key":"10.1016\/j.acra.2025.11.046_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115898","article-title":"Comparison of drug release and pharmacokinetics after transarterial chemoembolization using diverse lipiodol emulsions and drug-eluting beads","volume":"9","author":"Choi","year":"2014","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.acra.2025.11.046_bib30","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/ueg2.12365","article-title":"Postoperative adjuvant transarterial chemoembolisation improves survival of hepatocellular carcinoma patients with microvascular invasion: a multicenter retrospective cohort","volume":"11","author":"Luo","year":"2023","journal-title":"United Eur\u00a0Gastroenterol\u00a0J"},{"issue":"6","key":"10.1016\/j.acra.2025.11.046_bib31","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s13277-012-0504-2","article-title":"Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy","volume":"33","author":"Kohles","year":"2012","journal-title":"Tumour Biol\u00a0J\u00a0Int\u00a0Soc\u00a0Oncodevelop\u00a0Biol\u00a0Med"},{"issue":"1","key":"10.1016\/j.acra.2025.11.046_bib32","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jhep.2023.02.032","article-title":"TREM2+ macrophages suppress CD8+ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma","volume":"79","author":"Tan","year":"2023","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.acra.2025.11.046_bib33","first-page":"166","article-title":"Use of doxorubicin-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein invasion: a\u00a0prospective study","volume":"23","author":"Yu","year":"2023","journal-title":"J\u00a0Liver Cancer"},{"key":"10.1016\/j.acra.2025.11.046_bib34","article-title":"Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study","volume":"13","author":"Cai","year":"2022","journal-title":"Front\u00a0Immunol"},{"key":"10.1016\/j.acra.2025.11.046_bib35","article-title":"Hepatic arterial infusion chemotherapy plus lenvatinib and tislelizumab with or without transhepatic arterial embolization for unresectable hepatocellular carcinoma with portal vein tumor thrombus and high tumor burden: a multicenter retrospective study","volume":"10","author":"S","year":"2023","journal-title":"J\u00a0Hepatocell\u00a0Carcinoma"},{"issue":"1","key":"10.1016\/j.acra.2025.11.046_bib36","first-page":"1","article-title":"Recent advances in the management of hepatocellular carcinoma","volume":"30","author":"Sankar","year":"2024","journal-title":"Clin\u00a0Mol\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.acra.2025.11.046_bib37","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.hbpd.2025.03.001","article-title":"Adjuvant lenvatinib in combination with transarterial chemoembolization for hepatocellular carcinoma patients with high risk of postoperative recurrence: a multicenter prospective cohort study","volume":"24","author":"Chen","year":"2025","journal-title":"Hepatobiliary\u00a0Pancreat\u00a0Dis\u00a0Int HBPD INT"},{"key":"10.1016\/j.acra.2025.11.046_bib38","article-title":"Efficacy and safety of TACE combined with lenvatinib plus PD-1 inhibitors compared with TACE alone for unresectable hepatocellular carcinoma patients: a prospective cohort study","volume":"12","author":"Qu","year":"2022","journal-title":"Front\u00a0Oncol"},{"issue":"10","key":"10.1016\/j.acra.2025.11.046_bib39","doi-asserted-by":"crossref","first-page":"11513","DOI":"10.1002\/cam4.5880","article-title":"Efficacy and safety of TACE combined with lenvatinib and PD-1 inhibitors for unresectable recurrent HCC: a multicenter, retrospective study","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.acra.2025.11.046_bib40","article-title":"Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world","volume":"12","author":"Feng","year":"2022","journal-title":"Front\u00a0Oncol"},{"key":"10.1016\/j.acra.2025.11.046_bib41","article-title":"Survival benefits from adjuvant transcatheter arterial chemoembolization in patients undergoing liver resection for hepatocellular carcinoma: a\u00a0systematic review and meta-analysis","volume":"13","author":"Liang","year":"2020","journal-title":"Ther\u00a0Adv\u00a0Gastroenterol"}],"container-title":["Academic Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633225011304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633225011304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T23:27:01Z","timestamp":1772494021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1076633225011304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1076633225011304"],"URL":"https:\/\/doi.org\/10.1016\/j.acra.2025.11.046","relation":{},"ISSN":["1076-6332"],"issn-type":[{"value":"1076-6332","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Postoperative Adjuvant CTACE vs DEB-TACE Combined with Tislelizumab and Lenvatinib in BCLC Stage B\/C Hepatocellular Carcinoma: A Propensity Score-Matched Analysis of Survival Outcomes","name":"articletitle","label":"Article Title"},{"value":"Academic Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acra.2025.11.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Association of Academic Radiology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}